Relapsed or Refractory Mantle Cell Lymphoma (MCL) Market Outlook

Thelansis’s “Relapsed or Refractory Mantle Cell Lymphoma (MCL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Mantle Cell Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Relapsed or Refractory Mantle Cell Lymphoma (MCL) Overview

Relapsed or refractory mantle cell lymphoma (r/r MCL) is an aggressive B-cell lymphoma arising from cyclin D1-overexpressing mature B-cells — driven by the hallmark t(11;14) chromosomal translocation juxtaposing CCND1 and IGH loci — with relapsed or refractory disease representing a clinically challenging setting characterised by progressively shortened remission durations and poor prognosis. Resistance mechanisms include BTK mutation, TP53 aberrations, complex karyotype, and blastoid morphological transformation, each conferring worsening therapeutic outcomes. Patients present with progressive lymphadenopathy, splenomegaly, bone marrow infiltration, and gastrointestinal involvement; restaging PET-CT, repeat biopsy, TP53 mutational status, and Ki-67 proliferative index guide therapeutic stratification. Zanubrutinib and acalabrutinib are the definitive preferred covalent BTK inhibitors in r/r MCL, demonstrating superior efficacy and tolerability over first-generation ibrutinib, which has been withdrawn from this indication. Pirtobrutinib — a non-covalent BTK inhibitor — represents a critical and highly active salvage option specifically for covalent BTK inhibitor-pretreated MCL. Brexucabtagene autoleucel, a CAR-T therapy, delivers durable responses in heavily pretreated disease. Venetoclax-based combinations demonstrate meaningful activity in BTK inhibitor-refractory settings. Bendamustine-rituximab and bortezomib-based regimens retain utility in selected patients. Prognosis remains guarded despite therapeutic advances; clinical trial enrolment, multidisciplinary evaluation, and patient-centred palliative integration are indispensable to quality-focused care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)